Many women with a diagnosis of DCIS (Ductal Carcinoma in Situ) receive aggressive treatment ie mastectomy, and there is concern that a large proportion are being ‘overtreated’ because DCIS is not the same as invasive cancer and may never become so. Some clinicians would prefer DCIS to be called by another name, as it may not even be ‘pre-cancer’ – unless DCIS spreads it may never become a problem in a woman’s lifetime. The number of DCIS diagnoses has increased since breast screening was introduced and modern digital mammography picks up more changes (which may be just natural changes and never progress) than previous mammography. But no-one can tell which of these changes will become cancer. So all are likely to be treated.
A new trial is underway to compare surgery with active monitoring: LORIS (Low Risk DCIS) compares surgery with active monitoring.
Fallowfield L, et al., Low grade Ductal Carcinoma in situ (DCIS): How best to describe it?, The Breast (2014), http://dx.doi.org/10.1016/j.breast.2014.06.013
Journal of Clinical Oncology, 2014 ASCO Annual Meeting Abstracts.
Vol 32, No 15_suppl (May 20 Supplement), 2014: e12020
© 2014 American Society of Clinical Oncology
Abstract: What’s in a name: Describing ductal carcinoma in situ (DCIS). Lesley Fallowfield, Valerie A Jenkins, Lucy Matthews, Adele Francis and Daniel Rae